Evidence map›Paper›PMID 35628917›Full record

ArticleJournal of clinical medicine2022

The Combined Value of Type2 Inflammatory Markers in Chronic Obstructive Pulmonary Disease.

Yunhuan Liu, Guanhua Ma, Yan Mou, Xuanqi Liu, Wenjia Qiu, Yang Zheng, Huili Zhu, Haiyan Ge

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yunhuan LiuDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Guanhua MaDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Yan MouDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Xuanqi LiuDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Wenjia QiuDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Yang ZhengDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Huili ZhuDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Haiyan GeDepartment of Respiratory and Critical Care Medicine, Huadong Hospital, Fudan University, Shanghai 200040, China.
Fudan University · CNHuadong Hospital · CN

Funding

Bethune Research and Development Fund Project BJ-RW2020002JInvestigator-initiated clinical trials Foundation of Huadong Hospital HDLC2022018National Key R&D Program of China 2020YFC2009000National Key R&D Program of China 2020YFC2009001National Natural Science Foundation of China 81600056National Natural Science Foundation of China 81871100Scientific Research Project of Shanghai Municipal Health Commission 202140036Scientific Research Project of Shanghai Science and Technology Commission 21140902500Shanghai Health System Young Talent Fund Project Hengjie-Special Support Program 2022-020Shanghai Municipal Key Clinical Specialty shslczdzk02801
6 · The paper itself

Abstract

The roles of type2 inflammatory markers in chronic airway diseases have been assessed in previous studies. However, the relationship between the combined value of these biomarkers and chronic obstructive pulmonary disease (COPD) has not been fully elucidated. We aimed to investigate the roles of the combined value of the fraction of exhaled nitric oxide (FeNO) level and blood eosinophil count in COPD and the predictive capability of these biomarkers. In total, 266 patients were included in our analysis. When the two type2 biomarkers were assessed separately, there were limited correlations between either increased FeNO level or blood eosinophil count and decreased incidence of total exacerbation or frequency of mild exacerbation. Combining these two biomarkers strengthened their association with both incidence and frequency of acute exacerbation. In addition, during further assessment, simultaneously increased FeNO level and blood eosinophil count were associated with both mild and moderate acute exacerbation. Among the subjects included in this analysis, although the predictive capability was improved when these two biomarkers were combined, the improvement was not statistically significant, indicating the need to increase the sample size. The combination of FeNO level and blood eosinophil count exhibited strong and independent additive value in the assessment of acute exacerbation in COPD; simultaneously increased FeNO level and blood eosinophil count played a protective role in progression of COPD.

Indexed as

COPDeosinophilexacerbationfraction of exhaled nitric oxidetype2 immune response

Identifiers

PMID35628917
PMCPMC9144416
OpenAlexW4280632066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.